Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
04:08pm, Wednesday, 23'rd Jul 2025
NEW YORK , July 23, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 an
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
11:53am, Wednesday, 23'rd Jul 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you su
Sarepta's licensing patner Arrowhead expects near-term payments despite setbacks
08:05am, Wednesday, 23'rd Jul 2025
Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone payments from Sarepta Therapeutics as part of their licensing agreement, despite recent setbacks at the Cambridge,
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
01:30pm, Tuesday, 22'nd Jul 2025
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position r
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
10:35am, Tuesday, 22'nd Jul 2025
Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investo
Sarepta falls after gene therapy maker pauses Elevidys shipments in US
09:45am, Tuesday, 22'nd Jul 2025
Shares of Sarepta Therapeutics fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United S
NEW YORK , July 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Sarepta Therapeutics' stock slips further as company bows to FDA pressure to halt shipments
06:44am, Tuesday, 22'nd Jul 2025
Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy.
Sarepta Stock Falls. Why It's Caving Into the FDA and What Comes Next.
05:47am, Tuesday, 22'nd Jul 2025
The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.
Sarepta to pause gene therapy Elevidys shipments in US
08:13pm, Monday, 21'st Jul 2025
Sarepta Therapeutics said on Monday that it will pause all shipments of its Elevidys gene therapy in the United States after a muscular dystrophy patient who received a different, experimental treatme
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
07:40pm, Monday, 21'st Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Today, Sarepta Therapeuti
HC Wainwright's Kapoor talks if Sarepta shares could hit $0
06:16pm, Monday, 21'st Jul 2025
Mitchell Kapoor, HC Wainwright, joins 'Fast Money' to talk if Sarepta shares are at risk of hitting $0 and what its path forward is.
